Jiyeon Kim, PhD
Assistant Professor of Urology and Cellular & Molecular PhysiologyCards
About
Research
Publications
2026
Career pathways, part 18
Kim J, Harbauer A. Career pathways, part 18. Nature Metabolism 2026, 8: 1-3. PMID: 41507666, DOI: 10.1038/s42255-025-01432-5.Peer-Reviewed Original Research
2025
High KYNU Expression Is Associated with Poor Prognosis, KEAP1/STK11 Mutations, and Immunosuppressive Metabolism in Patient-Derived but Not Murine Lung Adenocarcinomas
Cai L, Rogers T, Jafarabad R, Vu H, Yang C, Novaresi N, Galán-Cobo A, Girard L, Ostrin E, Fahrmann J, Kim J, Heymach J, O’Donnell K, Xiao G, Xie Y, DeBerardinis R, Minna J. High KYNU Expression Is Associated with Poor Prognosis, KEAP1/STK11 Mutations, and Immunosuppressive Metabolism in Patient-Derived but Not Murine Lung Adenocarcinomas. Cancers 2025, 17: 1681. PMID: 40427178, PMCID: PMC12109616, DOI: 10.3390/cancers17101681.Peer-Reviewed Original ResearchLung adenocarcinomaPrognostic associationMethods:Cancer cell-intrinsicCell-intrinsic expressionImmune-cold tumorsImmune-infiltrated tumorsAssociated with poor prognosisMurine lung adenocarcinomaExpression patternsImmunosuppressive signalsKynurenine levelsMyeloid-derivedPreclinical modelsPrognostic markerPoor prognosisCo-mutationsFavorable outcomePrognostic accuracyPoor outcomePatient-derivedCell-intrinsicKidney cancerTryptophan catabolismMetabolic alterationsAmino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches
K. L, Lee H, Ha Y, Lee C, Kim J. Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches. Cell Reports 2025, 44: 115529. PMID: 40193251, PMCID: PMC12038367, DOI: 10.1016/j.celrep.2025.115529.Peer-Reviewed Original ResearchConceptsAmino acid metabolismMetabolic diversityAmino acidsAcid metabolismCentral carbon metabolismDiversity of amino acidsCarbon metabolismMetabolic plasticityRegions of solid tumorsMetabolic reprogrammingCancer metabolismSignaling moleculesAminoTumor immunitySolid tumorsTherapeutic responseClinical outcomesClinically relevant therapeutic interventionsMalignant transformationTherapeutic approachesMetabolismTumorCancerTherapeutic interventionsAcidPDK4 expression and tumor aggressiveness in prostate cancer
Lee E, Ha Y, Yoon B, Jeon M, Park D, Kim J, Kang J, Chung J, Kim B, Choi S, Kim H, Kim T, Yoo E, Kwon T. PDK4 expression and tumor aggressiveness in prostate cancer. Investigative And Clinical Urology 2025, 66: 227-235. PMID: 40312902, PMCID: PMC12058538, DOI: 10.4111/icu.20240434.Peer-Reviewed Original ResearchConceptsPyruvate dehydrogenase kinase 4 expressionProstate cancerPyruvate dehydrogenase kinase 4Cell linesKyungpook National University Chilgok HospitalCastration-resistant prostate cancerCancer cellsProstate cancer cell linesSpread of cancer cellsNormal prostate cellsProstate cancer metastasisNormal prostate tissueProstate cancer cellsAssociated with tumor invasionEpithelial-mesenchymal transition markersLNCaP cell lineCancer-related mortalityProstate cancer tissuesMatrigel-coated invasion chambersRegulation of aerobic glycolysisCancer cell linesHuman samplesProstate tissueDownstream signaling moleculesProstate cells
2024
Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone
Kim W, Kim K, Kang H, Byun Y, Piao X, Kim Y, Lee S, Yun S, Ha Y, Kim J, Kim I. Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone. Oncology Letters 2024, 29: 23. PMID: 39512501, PMCID: PMC11542165, DOI: 10.3892/ol.2024.14770.Peer-Reviewed Original Research635 Intraoperative 13C-glucose tracing and metabolomics of patient melanoma tumors reveal metabolic features associated with aggressive melanomas
Gill J, Rao A, Walsdorf R, Snyman M, Wix S, Brown A, Gard G, Kim J, Patricio J, Zacharias L, Solmonson A, Tillman B, Sharma R, Vandergriff T, Mathews T, Cai L, DeBerardinis R. 635 Intraoperative 13C-glucose tracing and metabolomics of patient melanoma tumors reveal metabolic features associated with aggressive melanomas. Journal Of Investigative Dermatology 2024, 144: s110. DOI: 10.1016/j.jid.2024.06.651.Peer-Reviewed Original ResearchConcurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer
Lee H, Muhammad N, Lieu E, Cai F, Mu J, Ha Y, Cao G, Suchors C, Joves K, Chronis C, Li K, Ducker G, Olszewski K, Cai L, Allison D, Bachert S, Ewing W, Wong H, Seo H, Kim I, Faubert B, Kim J, Kim J. Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer. Nature Metabolism 2024, 6: 1310-1328. PMID: 38877143, PMCID: PMC11809267, DOI: 10.1038/s42255-024-01066-z.Peer-Reviewed Original ResearchMeSH KeywordsAMP-Activated Protein Kinase KinasesAnimalsAntioxidantsCarcinoma, Non-Small-Cell LungCell Line, TumorGlycine HydroxymethyltransferaseHumansKelch-Like ECH-Associated Protein 1Lung NeoplasmsMiceMutationNF-E2-Related Factor 2Oxidative StressProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)ConceptsNon-small-cell lung cancerIn vivo therapeutic efficacySerine hydroxymethyltransferaseLung cancerTherapeutic efficacy of paclitaxelKRAS-mutant lung cancerHuman non-small-cell lung cancerLKB1 lossAggressive molecular subtypeEfficacy of paclitaxelSerine-glycine-one-carbon metabolismCellular sensitivity to oxidative stressSHMT inhibitorsTumor suppressor LKB1Sensitive to oxidative stressMolecular subtypesConcurrent lossOne-carbon unitsMetabolomics dataLoss of LKB1Concurrent mutationsTherapeutic strategiesKEAP1 lossRNA-seqCell death
2023
A century of the Warburg effect
Thompson C, Vousden K, Johnson R, Koppenol W, Sies H, Lu Z, Finley L, Frezza C, Kim J, Hu Z, Bartman C. A century of the Warburg effect. Nature Metabolism 2023, 5: 1840-1843. PMID: 37990075, DOI: 10.1038/s42255-023-00927-3.Peer-Reviewed Original ResearchMAD2-Dependent Insulin Receptor Endocytosis Regulates Metabolic Homeostasis.
Park J, Hall C, Hubbard B, LaMoia T, Gaspar R, Nasiri A, Li F, Zhang H, Kim J, Haeusler R, Accili D, Shulman G, Yu H, Choi E. MAD2-Dependent Insulin Receptor Endocytosis Regulates Metabolic Homeostasis. Diabetes 2023, 72: 1781-1794. PMID: 37725942, PMCID: PMC10658066, DOI: 10.2337/db23-0314.Peer-Reviewed Original ResearchConceptsIR endocytosisInsulin receptor endocytosisCell division regulatorsInsulin receptorProlongs insulin actionReceptor endocytosisTranscriptomic profilesInsulin stimulationEndocytosisMetabolic homeostasisCell surfaceGenetic ablationMetabolic functionsInsulin actionP31cometMad2BubR1DisruptionSignalingRegulatorHomeostasisAdipose tissueInteractionHepatic fat accumulationMetabolismMachine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database
Kim J, Lee S, Hong S, Kwak C, Jeong C, Kang S, Hong S, Kim Y, Chung J, Hwang E, Kwon T, Byun S, Jung Y, Lim J, Kim J, Oh H. Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database. Scientific Reports 2023, 13: 5778. PMID: 37031280, PMCID: PMC10082844, DOI: 10.1038/s41598-023-30826-2.Peer-Reviewed Original ResearchConceptsMethods of machine learningSynthetic minority oversampling techniqueF1 scoreMachine learningMinority oversampling techniqueData pre-processingStatistical methods of machine learningKorean renal cell carcinomaTraining dataFeature selectionImbalance problemRenal cell carcinomaOversampling techniqueML algorithmsPre-processingCell carcinomaElastic netPrediction modelPredictive performanceOncological outcomesOncological outcomes of renal cell carcinomaSubgroup analysisAccuracyOutcome of renal cell carcinomaLocalized Renal Cell Carcinoma
Academic Achievements & Community Involvement
News
News
- January 08, 2026Source: Nature Metabolism
Jiyeon Kim, PhD: Juggling Life Between Home and the Lab
- July 29, 2025
Yale Urology Research [Q2: April-June 2025]
- April 14, 2025Source: Cell Reports
Amino Acids in Cancer: Understanding Metabolic Plasticity and Divergence for Better Therapeutic Approaches
- January 16, 2025
Yale Urology Research [Q4: October-December 2024]
Get In Touch
Contacts
Email
Mailing Address
Yale School of Medicine
310 Cedar St., BML
New Haven, Connecticut 06519
United States
Locations
Brady Memorial Laboratory
Lab
310 Cedar Street, Fl 2, Rm 246
New Haven, CT 06510
General Information
203.737.6295